Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Melanoma
Interventions: VivaScope System; Device
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions: Tangible Boost, Placebo; Device · Other
Lead sponsor: Tangible Science; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Breast Cancer
Interventions: ZN-c5, Abemaciclib; Drug
Lead sponsor: Zeno Alpha Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Gilbert, Arizona • Charleston, South Carolina

Conditions: Atopic Dermatitis
Interventions: Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more

Conditions: Atopic Dermatitis, Atopic Eczema, Infantile Eczema, Hand Eczema
Interventions: Patient Educational Materials; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Atopic Dermatitis
Interventions: BRT-FC-83C; Device
Lead sponsor: Biomed Research & Technologies, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Atopic Dermatitis
Interventions: ZPL389 30mg, ZPL389 50mg, TCS and/or TCI; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Litchfield Park, Arizona • Fairborn, Ohio

Conditions: Atopic Dermatitis, Skin Diseases
Interventions: Orismilast modified release tablets, Placebo; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more

Conditions: Hereditary Angioedema (HAE), Angioedema
Interventions: Lanadelumab 150 mg, Lanadelumab 300 mg; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years and older
U.S. locations: 14
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more

Conditions: Atopic Dermatitis (AD), Eczema
Interventions: ARQ-234, Placebo; Biological · Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Miami, Florida • Plainfield, Indiana • Fair Lawn, New Jersey + 3 more

Conditions: Atopic Dermatitis
Interventions: Dupixent; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Hereditary Angioedema
Interventions: KVD900, Placebo; Drug · Other
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more

Conditions: Allergic Contact Dermatitis
Interventions: bacitracin (allergen); Drug
Lead sponsor: Mekos Laboratories AS; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions: Cream, 0.1% Uracil Cream; Drug
Lead sponsor: Nanometics (d.b.a. PHD Biosciences); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more

Conditions: Triple Negative Breast Cancer
Interventions: Olaparib Oral Product, Olaparib Oral Product in combination with Durvalumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Eczema, Atopic Dermatitis
Interventions: Sodium chloride tablets, Placebo Tablets; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Urticaria Chronic
Interventions: Briquilimab; Drug
Lead sponsor: Jasper Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more

Conditions: Chronic Inducible Urticaria
Interventions: Ligelizumab, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more

Conditions: Atopic Dermatitis
Interventions: SB414 2%, SB414 6%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more

Conditions: Smoking, Acne, Atopic Dermatitis, Aging
Interventions: Skin Surface Lipid Collection and Skin Barrier Function; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Psoriasis, Atopic Dermatitis
Interventions: CT-100-004-A, CT-100-004-B; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

Dupilumab De-escalation in Pediatric Atopic Dermatitis

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Dupixent and Narrowband UVB for Atopic Dermatitis

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Clinical Evaluation of Bacitracin

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

The Impact of Dietary Salt on the Severity of Eczema

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

Sebum Collection and Skin Barrier Function Analysis

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis